Top News

Feb 14, 2017
Evaluate and BioPharm International highlight the antibody-based therapeutics that may have 2017 launch dates in the United States.
Feb 13, 2017
EvaluatePharma and BioPharm International highlight the antibody-based therapeutics that may gain United States Regulatory approval in 2017.
Feb 13, 2017
Drug companies are pushing Congress to action on funding for FDA programs and staff to expedite drug reviews and approvals.
Feb 10, 2017
A total of 166 biotech executives penned an open letter expressing concern over President Donald Trump’s executive order on immigration.
Feb 07, 2017
Aggressive petitioning by ViroPharma kept a generic equivalent to Vancocin off the market for more than two years.
Feb 01, 2017
A change in the tax code could help the company create more jobs in the United States, while fewer FDA regulations could help reduce drug prices, according to Pfizer CEO Ian Read.
Jan 31, 2017
Trump met with pharma manufacturers and makes a statement focused on domestic manufacturing, FDA approvals, and drug pricing.
Jan 30, 2017
Alexandre Juillerat, PhD, innovation senior scientist at Cellectis, discusses novel construct UCART123, an investigational agent that is on deck to be the first gene-edited T-cell product in the United States.
Jan 26, 2017
By BioPharm International Editors
The companies will split Actelion’s drug discovery and early-stage clinical development assets into a new Swiss biopharmaceutical company.
Jan 24, 2017
Merck will pay a one-time fee of $625 million and additional royalties to BMS and Ono Pharmaceutical to settle the patent infringement case related to Keytruda.
lorem ipsum